Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apalutamide + strontium-89 + luteinizing hormone-releasing hormone analog
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Peptides
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
This combination therapy is a neoadjuvant regimen developed for patients with prostate cancer and limited bone metastases (≤10) who are candidates for radical prostatectomy. It combines **apalutamide**, a potent second-generation androgen receptor inhibitor, with **strontium-89 (89Sr)**, a bone-seeking radiopharmaceutical that mimics calcium and localizes to areas of active bone turnover to deliver localized beta radiation. The regimen also includes a **luteinizing hormone-releasing hormone (LHRH) analog** to achieve androgen deprivation. This intensive systemic and bone-targeted approach is being investigated by Zhujiang Hospital to improve pathological complete response rates and progression-free survival by targeting both the primary tumor and micrometastatic osseous disease prior to surgical intervention.
- Other names
- Apalutamide + 89Sr + ADTApalutamide + Strontium-89 + LHRH Analog
02
Targets
AR (Adrenergic receptors)GnRHR (Gonadotropin-releasing hormone receptor)DNA
Beyond the preview
Go deeper on apalutamide + strontium-89 + luteinizing hormone-releasing hormone analog.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apalutamide + strontium-89 + luteinizing hormone-releasing hormone analog.